ArticleJournal of gynecologic oncology2021
Recurrence risk factors in stage IA grade 1 endometrial cancer.
Article in Journal of gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Evaluation of prognostic significance of lymphovascular space invasion in early stage endometrial cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Association of Tumor Size With Myometrial Invasion, Lymphovascular Space Invasion, Lymph Node Metastasis, and Recurrence in Endometrial Cancer: A Meta-Analysis of 40 Studies With 53,276 Patients.Frontiers in oncology · 2022Pooled it
- Tumor immune microenvironment and epithelial-mesenchymal transition in recurrence of low-grade stage IA endometrial endometrioid carcinoma.BMC cancer · 2026Article
- Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report.Frontiers in oncology · 2026Article
- Impact of Prolonged Surgical Waiting Time on 5-Year Progression-Free Survival in Patients With Endometrial Cancer.The journal of obstetrics and gynaecology research · 2026Article
- The updated 2023 staging of endometrial cancer: tips for MRI interpretation.Abdominal radiology (New York) · 2026Review
- Clinicopathological and preoperative biomarkers associated with recurrence after primary surgical treatment for endometrial cancer.Frontiers in oncology · 2026Article
- Risk Factors for the Prognosis of Endometrioid Endometrial Cancer: A Chinese Cohort Study.Obstetrics and gynecology international · 2026Article
- Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.Oncology and therapy · 2025Article
- Prognostic characteristics and recurrence patterns of grade 1 endometrial carcinoma: a large retrospective analysis of a tertiary center.Translational cancer research · 2025Article
- Multifactorial construction of low-grade and high-grade endometrial cancer recurrence prediction models.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Article
- Current Unveiling Key Research Trends in Endometrial Cancer: A Comprehensive Topic Modeling Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Preoperative prediction of aggressive endometrial cancer using multiparametric MRI-based deep transfer learning models.Frontiers in oncology · 2025Article
- Construction and validation of a Cox regression-based nomogram model for predicting recurrence risk in early endometrial cancer.American journal of cancer research · 2025Article
- Prognostic values of tumor size and location in early stage endometrial cancer patients who received radiotherapy.Journal of gynecologic oncology · 2024Article
- Predicting Risk Stratification in Early-Stage Endometrial Carcinoma: Significance of Multiparametric MRI Radiomics Model.Journal of imaging informatics in medicine · 2024Article
- High PLK3 levels are linked with less tumor invasion, lower FIGO stage and better prognosis of endometrial cancer.Biomarkers in medicine · 2024Article
- Predictors of recurrence and survival in lymphovascular space invasion negative early-stage endometrioid endometrial cancer patients.Journal of the Turkish German Gynecological Association · 2023Article
- The clinical significance of lymphovascular space invasion in patients with low-risk endometrial cancer.Revista da Associacao Medica Brasileira (1992) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPatients with early-stage endometrial cancers (EC) with disease recurrences have worse survival outcomes. The purpose of this study was to identify clinical and pathologic factors that predict for all recurrences in stage IA grade 1 (IAG1) EC.
methodsRecords from patients diagnosed with EC were retrospectively reviewed. Baseline characteristics of 222 patients with IAG1 EC who underwent surgical resection were analyzed. Cox proportional hazard analysis was used to identify univariate and multivariate risk factors that predict for recurrence.
resultsSeventeen (7.65%) patients had recurrences. The 3-year cumulative incidence of recurrence were significantly higher for patients with time from biopsy to surgery ≥6 months (54% vs. 8%, p=0.003), simple hysterectomy with ovarian preservation vs. total hysterectomy and bilateral salpingo-oophorectomy (31% vs. 9%, p=0.032), any myometrial invasion vs. no invasion (18% vs. 2%, p=0.004), and tumor size ≥2 cm (15% vs. 2%, p=0.021). On, multivariate analysis, any myometrial invasion, increasing time from biopsy to surgery, and larger tumor size were independent predictors of any recurrence. Patients with recurrences had worse outcomes than those without (5-year overall survival [OS]=60%; 95% confidence interval [CI]=16%-86% vs. 5-year OS=95%; 95% CI=87%-99%, respectively, p=0.003).
conclusionTime from biopsy to surgery, larger tumors, and myometrial invasion are the most important predictors of recurrence. Though the recurrence rates are generally low in IAG1 EC, the survival rate for the patients with recurrences was worse than those without. Identification of additional recurrence risk factors can help select patients who may benefit from adjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.